Enhancing TIL Selection to Improve Specificity & Functionality
Time: 1:30 pm
day: Conference Day Two PM
Details:
- Enriching highly tumor-reactive CD8+ TILs by selecting CD39/ CD103 double-positive cells
- Expanding exhausted TILs into billions while retaining tumorkilling functionality
- Demonstrating long-term persistence, trafficking, and efficacy in IL-2-supported clinical models
